BENEFITS OF HIGH VERSUS LOW DOSE UPADACITINIB AS MAINTENANCE TREATMENT IN ULCERATIVE COLITIS PATIENTS WHO WERE RESPONDERS TO 8-WEEK INDUCTION WITH UPADACITINIB: RESULTS FROM THE U-ACHIEVE PHASE 3 MAINTENANCE TRIAL

Brian G. Feagan  1     Gareth Parkes  2     Pascal Juillerat  3     Krisztina Barbara Gecse  4     Xuan Yao  5     Wen Zhou  6     Huiwen Deng  6     Dapo Ilo  7     Yuri Sanchez Gonzalez  7     Peter D.R. Higgins  8    
1 Western University, London, Canada
2 Barts Health NHS Trust, London, United Kingdom
3 Gastroenterology, Department of Visceral Surgery and Medicine, Inselspital Bern and Bern University, Bern, Switzerland
4 Location AMC, Amsterdam UMC, Amsterdam, Netherlands
5 AbbVie Inc., North Chicago, United States
6 AbbVie, Inc., North Chicago, United States
7 AbbVie Inc., North Chicago, United Kingdom
8 University of Michigan, Ann Arbor, United States

Topic
IBD, Nurses, Primary Care

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing